922 related articles for article (PubMed ID: 27217448)
1. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
Cortes JE; Saglio G; Kantarjian HM; Baccarani M; Mayer J; Boqué C; Shah NP; Chuah C; Casanova L; Bradley-Garelik B; Manos G; Hochhaus A
J Clin Oncol; 2016 Jul; 34(20):2333-40. PubMed ID: 27217448
[TBL] [Abstract][Full Text] [Related]
2. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.
Hughes TP; Saglio G; Quintás-Cardama A; Mauro MJ; Kim DW; Lipton JH; Bradley-Garelik MB; Ukropec J; Hochhaus A
Leukemia; 2015 Sep; 29(9):1832-8. PubMed ID: 26118315
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Kantarjian HM; Shah NP; Cortes JE; Baccarani M; Agarwal MB; Undurraga MS; Wang J; Ipiña JJ; Kim DW; Ogura M; Pavlovsky C; Junghanss C; Milone JH; Nicolini FE; Robak T; Van Droogenbroeck J; Vellenga E; Bradley-Garelik MB; Zhu C; Hochhaus A
Blood; 2012 Feb; 119(5):1123-9. PubMed ID: 22160483
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Shah NP; Rousselot P; Schiffer C; Rea D; Cortes JE; Milone J; Mohamed H; Healey D; Kantarjian H; Hochhaus A; Saglio G
Am J Hematol; 2016 Sep; 91(9):869-74. PubMed ID: 27192969
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Fujisawa S; Nakamae H; Ogura M; Ishizawa K; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Akiyama H; Onishi S
Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
[TBL] [Abstract][Full Text] [Related]
7. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
[TBL] [Abstract][Full Text] [Related]
8. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.
Nakamae H; Fujisawa S; Ogura M; Uchida T; Onishi Y; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Ohashi K; Li L; Miyoshi M
Int J Hematol; 2017 Jun; 105(6):792-804. PubMed ID: 28341918
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
Gore L; Kearns PR; de Martino ML; Lee ; De Souza CA; Bertrand Y; Hijiya N; Stork LC; Chung NG; Cardos RC; Saikia T; Fagioli F; Seo JJ; Landman-Parker J; Lancaster D; Place AE; Rabin KR; Sacchi M; Swanink R; Zwaan CM
J Clin Oncol; 2018 May; 36(13):1330-1338. PubMed ID: 29498925
[TBL] [Abstract][Full Text] [Related]
11. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
12. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
13. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
Kwak JY; Kim SH; Oh SJ; Zang DY; Kim H; Kim JA; Do YR; Kim HJ; Park JS; Choi CW; Lee WS; Mun YC; Kong JH; Chung JS; Shin HJ; Kim DY; Park J; Jung CW; Bunworasate U; Comia NS; Jootar S; Reksodiputro AH; Caguioa PB; Lee SE; Kim DW
Clin Cancer Res; 2017 Dec; 23(23):7180-7188. PubMed ID: 28939746
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.
Chuah CT; Nakamae H; Shen ZX; Bradley-Garelik MB; Kim DW
Leuk Lymphoma; 2014 Sep; 55(9):2093-100. PubMed ID: 24289108
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Naqvi K; Jabbour E; Skinner J; Anderson K; Dellasala S; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
Cancer; 2020 Jan; 126(1):67-75. PubMed ID: 31553487
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Hochhaus A; Müller MC; Radich J; Branford S; Kantarjian HM; Hanfstein B; Rousselot P; Kim DW; Lipton JH; Bleickardt E; Lambert A; Hughes TP
Leukemia; 2009 Sep; 23(9):1628-33. PubMed ID: 19641527
[TBL] [Abstract][Full Text] [Related]
19. Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.
Murai K; Yamaguchi K; Ito S; Miyagishima T; Shindo M; Wakasa K; Inomata M; Nagashima T; Kondo T; Fujimoto N; Yamamoto S; Yonezumi M; Oyake T; Kowata S; Tsukushi Y; Mine T; Meguro K; Ikeda K; Watanabe R; Saito S; Sato S; Tajima K; Chou T; Kubo K; Oba K; Sakamoto J; Ishida Y;
Eur J Haematol; 2018 Jan; 100(1):27-35. PubMed ID: 28895203
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter Prospective Study in China.
Yu W; Du X; Wang W; Lou J; Liu P; Meng L; Jin J
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e867-e873. PubMed ID: 35842355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
